title: A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway.
abstract: A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.
authors: Department of Otolaryngology-Head and Neck Surgery; Asahikawa Medical University; Asahikawa, Japan ; Immunology Program; Moffitt Cancer Center; Tampa, FL USA.
authors: Toshihiro
authors: T
authors: Nagato
authors: Cancer Immunology, Inflammation and Tolerance Program; Georgia Regents University Cancer Center; Augusta, GA USA.
authors: Esteban
authors: E
authors: Celis
keywords: PD-1; PD-L1; cancer immunotherapy; colon cancer; lung cancer; melanoma; poly-IC